View Older Stories View More Recent Stories
-
Wells Fargo Resumes Guardant Health (GH) at Overweight
-
Guardant Health partners with PathGroup to expand Shield blood test access
-
Guardant Health (GH) PT Raised to $70 at BTIG
-
Evercore ISI Reiterates Outperform Rating on Guardant Health (GH)
-
Leerink Partners Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health reports improved Shield cancer test performance
-
Guardant Health (GH) surges in after-hours trade
-
Guardant Health (GH) PT Raised to $60 at Scotiabank
-
Guardant Health (GH) Tops Q2 EPS by 28c, provides guidance
-
Evercore ISI Reiterates Outperform Rating on Guardant Health (GH)
-
Braidwood ruling positive for Exact Sciences (EXAS) and Guardant Health (GH) - Stifel
-
Supreme Court Braidwood ruling positive for Guardant Health (GH) and Exact Sciences (EXAS) - Barclays
-
Guardant Health (GH) PT Raised to $65 at Mizuho
-
UBS Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) Granted FDA Breakthrough Device Designation for Multi-Cancer Detection (MCD) Test
-
Leerink Partners Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Guardant Health (GH) announces new features for Guardant 360 Liquid test
-
Guardant Health (GH) adds full suite of IHC testing
-
Guardant Health (GH) Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health (GH) PT Raised to $57 at Scotiabank
-
Guardant Health (GH) PT Raised to $65 at Canaccord Genuity
-
Guardant Health (GH) Tops Q1 EPS by 26c, Updates Guidance
-
Guardant Health (GH) Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health (GH) Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health (GH) Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Mizuho Starts Guardant Health (GH) at Outperform
-
Guardant Health (GH) partners with Bayshore HealthCare to offer testing portfolio in Canada
-
Guardant Health's (GH) Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Positive estimate revisions should drive this stock higher still - analyst
-
TD Cowen Reiterates Buy Rating on Guardant Health (GH)
-
Citi Reiterates Buy Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health (GH) Receives ADLT Status From CMS for Shield Blood Test
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Guardant Health (GH) PT Raised to $52 at Morgan Stanley
-
Guardant Health (GH) PT Raised to $60 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $60 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $60 at BTIG
-
Guardant Health (GH) PT Raised to $60; Bernstein: 'We Remain Bullish on the Stock'
-
Guardant Health (GH) PT Raised to $60 at Citi
-
Guardant Health (GH) PT Raised to $56 at BofA Securities
-
Guardant Health (GH) Tops Q4 EPS by 16c; offers guidance
-
Bernstein SocGen Group Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health (GH) 1.74M Share Block Trades
-
Guardant Health (GH) Announces Debt Exchange Transactions
-
Guardant Health (GH) to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools
-
Barclays Starts Guardant Health (GH) at Overweight
